charlotte costentin

Dr. charlotte costentin


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2019 in Liver International
Verified
Journal Article
Closed access
PDF file
SFSandrine Faivre
Sandrine Faivre
Armando SantoroArmando Santoro
Armando Santoro
RKRobin K. Kelley
Robin K. Kelley
EGEd Gane
Ed Gane
CCcharlotte costentin
charlotte costentin
GGGianluigi Giannelli
Gianluigi Giannelli

1 August 2018 in Gastroenterology
Verified
Journal Article
Closed access
PDF file
CCcharlotte costentin
charlotte costentin
RLRichard Layese
Richard Layese
VBValérie Bourcier
Valérie Bourcier
CCCarole Cagnot
Carole Cagnot
PMPatrick Marcellin
Patrick Marcellin
SHSophie Hillaire
Sophie Hillaire

26 May 2017 in Liver Transplantation
Verified
Journal Article
Closed access
PDF file
BMBenjamin Menahem
Benjamin Menahem
JLJean Lubrano
Jean Lubrano
CDChristophe Duvoux
Christophe Duvoux
AMAndrea Mulliri
Andrea Mulliri
AAArnaud Alves
Arnaud Alves
ALAlexis Laurent
Alexis Laurent

28 March 2018 in Cancer
Verified
Journal Article
Closed access
PDF file
CCcharlotte costentin
charlotte costentin
AMAbbas Mourad
Abbas Mourad
PLPierre Lahmek
Pierre Lahmek
XCXavier Causse
Xavier Causse
APAlexandre Pariente
Alexandre Pariente
FGfor the CHANGH Study Group
for the CHANGH Study Group

1 August 2018 in Journal of Hepatology
Verified
Journal Article
Closed access
JCJulia Chalaye
Julia Chalaye
CCcharlotte costentin
charlotte costentin
ALAlain Luciani
Alain Luciani
GAGiuliana Amaddeo
Giuliana Amaddeo
NGNathalie Ganne-Carrié
Nathalie Ganne-Carrié
JNJean-Charles Nault
Jean-Charles Nault

7 April 2023 in Clinical Gastroenterology and Hepatology
Verified
Journal Article
Open access
CCClemence M Canivet
Clemence M Canivet
MZMing-Hua Zheng
Ming-Hua Zheng
SQSami Qadri
Sami Qadri
LVLuisa Vonghia
Luisa Vonghia
KCKee-Huat Chuah
Kee-Huat Chuah
JBJérôme Boursier
Jérôme Boursier
Drug development in nonalcoholic steatohepatitis (NASH) is hampered by a high screening failure rate that reaches 60% to 80% in therapeutic trials, mainly because of the absence of fibrotic NASH on baseline liver histology. MACK-3, a blood test including 3 biomarkers (aspartate aminotransferase, homeostasis model assessment, and cytokeratin 18), recently was developed for the noninvasive diagnosis of fibrotic NASH. We aimed to validate the diagnostic accuracy of this noninvasive test in an international multicenter study. A total of 1924 patients with biopsy-proven nonalcoholic fatty liver disease from 10 centers in Asia, Australia, and Europe were included. The blood test MACK-3 was calculated for all patients. FibroScan-aspartate aminotransferase score (FAST), an elastography-based test for fibrotic NASH, also was available in a subset of 655 patients. Fibrotic NASH was defined as the presence of NASH on liver biopsy with a Nonalcoholic Fatty Liver Disease Activity Score of 4 or higher and fibrosis stage of F2 or higher according to the NASH Clinical Research Network scoring system. The area under the receiver operating characteristic of MACK-3 for fibrotic NASH was 0.791 (95% CI 0.768-0.814). Sensitivity at the previously published MACK-3 threshold of less than 0.135 was 91% and specificity at a greater than 0.549 threshold was 85%. The MACK-3 area under the receiver operating characteristic was not affected by age, sex, diabetes, or body mass index. MACK-3 and FAST results were well correlated (Spearman correlation coefficient, 0.781; P < .001). Except for an 8% higher rate of patients included in the grey zone, MACK-3 provided similar accuracy to that of FAST. Both tests included 27% of patients in their rule-in zone, with 85% specificity and 35% false positives (screen failure rate). The blood test MACK-3 is an accurate tool to improve patient selection in NASH therapeutic trials.